France Alzheimers Disease Diagnostics Market Insight
The French Alzheimer's disease diagnostics market size is growing at a 11.3% CAGR, driven by an aging population, increasing prevalence of neurodegenerative disorders, and rising demand for early and accurate diagnosis supported by advancements in imaging and biomarker-based testing.
France Alzheimer’s Disease Diagnostics Market Insights Forecasts to 2035
- The France Alzheimer’s Disease Diagnostics Market Size Was Estimated at USD 487.9 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 11.3% from 2025 to 2035
- The France Alzheimer’s Disease Diagnostics Market Size is Expected to Reach USD 1423 Million by 2035
Notable Insights for France Alzheimer’s Disease Diagnostics Market
- By diagnostic type, the imaging segment dominates the market, generating approximately USD 130 million in revenue in 2024, driven by high adoption of MRI and PET scans.
- By diagnostic type, the biomarker tests segment is the fastest-growing, expected to expand at a CAGR of around from 2025 to 2035, supported by advancements in blood-based and CSF diagnostic technologies.
- Approximately 60% of Alzheimer’s diagnostics in France are conducted in hospitals, while nearly 35% involve biomarker-based testing, reflecting increasing adoption of advanced diagnostic methods. Additionally, France holds a significant share in the European neurodiagnostics market.
- Around 50% of diagnostic procedures involve imaging techniques such as MRI and PET, while nearly 25% focus on early-stage detection through biomarker assays, highlighting the shift toward early and accurate diagnosis.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the France Alzheimer’s Disease Diagnostics market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in France Alzheimer’s Disease Diagnostics Market
- Roche Diagnostics
- Siemens Healthineers
- GE HealthCare
- Philips Healthcare
- Abbott Laboratories
- Fujirebio
- Bio-Rad Laboratories
- Thermo Fisher Scientific
- Quanterix Corporation
- Danaher Corporation
- Others
Recent Developments:
- In April 2026, Roche Diagnostics expanded its Alzheimer’s diagnostic portfolio with advanced biomarker testing solutions for early detection.
- In January 2026, Siemens Healthineers enhanced its neuroimaging systems with AI-driven analysis tools for improved diagnostic accuracy.
Market Segmentation:
France Alzheimer’s Disease Diagnostics Market, By Diagnostic Type
- Imaging (MRI, PET)
- Biomarker Tests
- Cognitive Assessment
- Others
France Alzheimer’s Disease Diagnostics Market, By End-User
- Hospitals
- Diagnostic Centers
- Research Institutes
Expert Views:
The France Alzheimer’s disease diagnostics market is evolving toward early detection and precision diagnostics. Experts expect strong growth in biomarker-based testing and AI-driven imaging solutions, improving diagnostic accuracy, enabling earlier intervention, and supporting better disease management outcomes.